175 related articles for article (PubMed ID: 35810257)
1. LncRNA H19 is a potential biomarker and correlated with immune infiltration in thyroid carcinoma.
Sahin Y
Clin Exp Med; 2023 Jul; 23(3):841-851. PubMed ID: 35810257
[TBL] [Abstract][Full Text] [Related]
2. Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer.
Su Y; Xu B; Li J; Shen Q; Lei Z; Ma M; Zhang F; Hu T
Ann Med; 2023 Dec; 55(1):1298-1316. PubMed ID: 36974635
[TBL] [Abstract][Full Text] [Related]
3. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma.
Wang Y; Zhang Y; Li Y; Huang J
Sci Rep; 2024 Mar; 14(1):6813. PubMed ID: 38514754
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma.
Du JW; Li GQ; Li YS; Qiu XG
Sci Rep; 2021 Aug; 11(1):16239. PubMed ID: 34376710
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
Zhang X; Meng X; Wang P; Luan C; Wang H
Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
[TBL] [Abstract][Full Text] [Related]
6. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.
Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J
Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889
[TBL] [Abstract][Full Text] [Related]
7. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis.
Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T
BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405
[TBL] [Abstract][Full Text] [Related]
8. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis.
Liu N; Zhou Q; Qi YH; Wang H; Yang L; Fan QY
Exp Mol Pathol; 2017 Aug; 103(1):71-77. PubMed ID: 28655518
[TBL] [Abstract][Full Text] [Related]
9. Construction and Validation of an Immune-Related lncRNA Prognosis Model for Thyroid Cancer.
Li Z; Wang H; Deng X; Zhang J; Wang L; Tang W; You W; Nian W
Comb Chem High Throughput Screen; 2022; 25(13):2217-2227. PubMed ID: 35209814
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential LncRNAs as papillary thyroid carcinoma biomarkers based on integrated bioinformatics analysis using TCGA and RNA sequencing data.
Feng JL; Zheng WJ; Xu L; Zhou QY; Chen J
Sci Rep; 2023 Mar; 13(1):4350. PubMed ID: 36928327
[TBL] [Abstract][Full Text] [Related]
11. Identification of disulfidptosis-associated genes and characterization of immune cell infiltration in thyroid carcinoma.
Song S; Zhou J; Zhang L; Sun Y; Zhang Q; Tan Y; Zhou X; Yu J
Aging (Albany NY); 2024 Jun; 16():. PubMed ID: 38836761
[TBL] [Abstract][Full Text] [Related]
12. lncRNA DUXAP8 inhibits papillary thyroid carcinoma cell apoptosis via sponging the miR‑20b‑5p/SOS1 axis.
Pang R; Yang S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760128
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-coding RNA related prognosis biomarkers based on ceRNA network in thyroid cancer.
Fang X; Chen X; Gao J; Tong L
Front Genet; 2023; 14():1157438. PubMed ID: 37153003
[No Abstract] [Full Text] [Related]
14. HSPA5 is a prognostic biomarker correlated with immune infiltrates in thyroid carcinoma.
Dong W; Du D; Huang H
Endokrynol Pol; 2022; 73(4):680-689. PubMed ID: 36059163
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer.
Zhang L; Yu S; Hong S; Xiao X; Liao Z; Li Y; Xiao H
BMC Med Genomics; 2023 Oct; 16(1):234. PubMed ID: 37798795
[TBL] [Abstract][Full Text] [Related]
16. Systematic analysis of the prognosis and immune infiltration of E2Fs in thyroid carcinoma.
Fu X; Zhou X; Ji F; He Q; Qiu X
Front Genet; 2023; 14():1215984. PubMed ID: 37560385
[No Abstract] [Full Text] [Related]
17. The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma.
Wu P; Shi J; Sun W; Zhang H
Bioengineered; 2021 Dec; 12(2):12854-12866. PubMed ID: 34898340
[TBL] [Abstract][Full Text] [Related]
18. The Prognostic Value of PERK in Cancer and Its Relationship With Immune Cell Infiltration.
Wang P; Han L; Yu M; Cao Z; Li X; Shao Y; Zhu G
Front Mol Biosci; 2021; 8():648752. PubMed ID: 33937330
[No Abstract] [Full Text] [Related]
19. Downregulation of long noncoding RNA H19 contributes to the proliferation and migration of papillary thyroid carcinoma.
Lan X; Sun W; Dong W; Wang Z; Zhang T; He L; Zhang H
Gene; 2018 Mar; 646():98-105. PubMed ID: 29287713
[TBL] [Abstract][Full Text] [Related]
20. Identification of m6A-related lncRNAs for thyroid cancer recurrence.
Wang X; Su D; Wei Y; Liu S; Gao S; Tian H; Wei W
Gland Surg; 2023 Jan; 12(1):39-53. PubMed ID: 36761480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
